SCHEMBL12373570

SCHEMBL12373570

C[C@H]1CC[C@@H](c2nc3cc(C#C[Si](C)(C)C)ccc3[nH]2)N1C(=O)OC(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 12/20 0.42
GABRG2 P18507 11/20 0.42
GABRB3 P28472 11/20 0.42
GABRA5 P31644 11/20 0.42
GABRA3 P34903 10/20 0.42
GABRA2 P47869 10/20 0.42
GABRA6 Q16445 7/20 0.42
GABRA4 P48169 6/20 0.37
UCHL1 P09936 1/20 0.34
GABRB2 P47870 1/20 0.34
GRM5 P41594 2/20 0.32
GPR119 Q8TDV5 1/20 0.32
CETP P11597 1/20 0.32
HCRTR1 O43613 1/20 0.31
HCRTR2 O43614 1/20 0.31
AAK1 Q2M2I8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10200239 0.88 GABRG2 (0.40) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL12373562 0.85 GABRA1 (0.42) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL19488770 0.85 GABRA1 (0.42) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL12373606 0.85 GABRA5 (0.38) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL12373556 0.84 UCHL1 (0.43) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL19488778 0.83 GABRG2 (0.39) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL12373508 0.83 HCRTR1 (0.37) HCRTR1HCRTR2
SCHEMBL19488584 0.80 YAP1 (0.42)
SCHEMBL12373673 0.78 GABRA1 (0.37) GABRA1GABRG2GABRB3GABRA3GABRA2
SCHEMBL10202464 0.78 GABRA1 (0.37) GABRA1GABRG2GABRB3GABRA3GABRA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2601188-B1 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-10-18 EP disclosed
US-8809548-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-19 US disclosed
US-8809548-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-19 US disclosed
US-20140205564-A1 Hepatitis C Virus Inhibitors BRISTOL MYERS SQUIBB CO (US) 2014-07-24 US disclosed
US-20140205564-A1 Hepatitis C Virus Inhibitors BRISTOL MYERS SQUIBB CO (US) 2014-07-24 US disclosed
US-8394968-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-03-12 US disclosed
US-20110195044-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2011-08-11 US disclosed
US-20100215616-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2010-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100215616-A1 Hepatitis C Virus Inhibitors HAVCR2, PYGL, HCCS GABRA1 3946/4885GABRG2 3280/4885GABRB3 2346/4885
US-20110195044-A1 Hepatitis C Virus Inhibitors HAVCR2, PYGL, HCCS GABRA1 3946/4885GABRG2 3280/4885GABRB3 2346/4885
US-20140205564-A1 Hepatitis C Virus Inhibitors HAVCR2, PYGL, HCCS GABRA1 3946/4885GABRG2 3280/4885GABRB3 2346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.